<DOC>
	<DOCNO>NCT00796744</DOCNO>
	<brief_summary>The purpose study assess experimental drug , DSC127 , safe , well tolerate , different dos effect heal chronic foot ulcer diabetic subject .</brief_summary>
	<brief_title>Safety Efficacy Study DSC127 Treating Subjects With Diabetic Ulcers</brief_title>
	<detailed_description>This study design randomize , parallel-group , double-blind , placebo-controlled trial . After 14-day baseline evaluate ulcer heal ensure DU chronic , 4-week active treatment follow 8 week observation assessment treatment compare effect two concentration DSC127 placebo ( n = 25 evaluable subject per group ; n=75 total evaluable subject ) identify optimal dose DSC127 . Sustained tissue integrity evaluate subject follow-up period study week 16 24 . Subjects randomize 1:1:1 ratio one three treatment group . Group 1 : Placebo Vehicle Control Group 2 : 0.03 % DSC127 Vehicle Group 3 : 0.01 % DSC127 Vehicle The four week treatment period require daily application treatment wound site . First application week clinic remainder week patient self-administers treatment . If wound healing occur treatment assessment period final assessment visit conduct integrity assess four twelve week later ( usually week 16 24 study ) .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<mesh_term>Angiotensin I ( 1-7 )</mesh_term>
	<criteria>Have least one chronic nonhealing Wagner Grade 1 Grade 2 plantar neuropathic diabetic ulcer 1.06.0 cm2 midfoot forefoot , include toe exclude heel . ABI great 0.7 neuroischemic great 0.8 neuropathic DU TcPO2 great 40 mm Hg great toe systolic pressure great 50 mmHg Type I Type II diabetes metabolic control Female subject must negative pregnancy test willing use acceptable method birth control duration study Exposure investigational product within last 30 day , know hypersensitivity study medication component Chronic renal insufficiency and/or chronic liver dysfunction Resting blood pressure ( time initial visit Screening Period ) exceed 160 systolic and/or 90 diastolic mmHg 3 consecutive reading least 15 minute apart Malignancy kind Receiving hemodialysis CAPD Current history drug abuse , and/or know HIV positive Prior radiation therapy foot study Current use corticosteroid ( within past 8 week ) , immunosuppressant ( within past 8 week ) , use biologic agent include growth factor skin equivalent ( Regranex , Apligraft , Dermagraft ) past 90 day Ulcer deem clinically infected require topical antimicrobial agent know affect wound healing , subject take systemic antibiotic 7 day reason Sicklecell anemia , Raynaud 's peripheral vascular disease Wagner Grade 3 high DU , deep abscess infection joint tendon , gangrene osteomyelitis An EKG mark baseline prolongation QT/QTc interval</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Diabetes mellitus</keyword>
	<keyword>Diabetic neuropathy</keyword>
	<keyword>Peripheral vascular disease</keyword>
	<keyword>Infection</keyword>
	<keyword>Topical application</keyword>
	<keyword>plantar foot ulcer</keyword>
</DOC>